Discover and read the best of Twitter Threads about #reversemerger
Most recents (1)
Here’s a closer look at TIGIT and its potential in #cancer therapy. This target is primed to gain more traction in immuno-oncology this year. (Thread below)
Key players developing anti-TIGIT therapies are $RHHBY $MRK $BMY $RCUS $ALPMY $BGNE $CGEN $SGEN $MREO $IVBXF & @iTeosTx
Key players developing anti-TIGIT therapies are $RHHBY $MRK $BMY $RCUS $ALPMY $BGNE $CGEN $SGEN $MREO $IVBXF & @iTeosTx
TIGIT is an inhibitory receptor expressed by activated T-cells, T-regs & NK cells
- Ligand for TIGIT (PVR) is expressed in multiple tumor types
- Activation suppresses T-cell activity
- Upregulated during PD-1 blockade
@Cancer_Cell paper (open access): cell.com/cancer-cell/fu…
- Ligand for TIGIT (PVR) is expressed in multiple tumor types
- Activation suppresses T-cell activity
- Upregulated during PD-1 blockade
@Cancer_Cell paper (open access): cell.com/cancer-cell/fu…
A key TIGIT question is the role of FcƔR and antibody-dependent cell-mediated cytotoxicity (ADCC).
$RHHBY & $MRK support FcƔR ADCC benefit due to T-reg depletion & myeloid cell reprogramming. $RCUS states the opposite as this ADCC activity may also deplete T-effector & NK cells.
$RHHBY & $MRK support FcƔR ADCC benefit due to T-reg depletion & myeloid cell reprogramming. $RCUS states the opposite as this ADCC activity may also deplete T-effector & NK cells.
